Pfizer Corporation

Array Biopharma Inc.

Peloton Therapeutics, Inc.

Amgen Inc.

James P Rizzi

Mark C Munson

Bin Wang

Martha E Rodriguez

Hanbiao Yang

Stephen T Schlachter

Paul Wehn

Eli M Wallace

John A Josey

Jonas Grina

Darryl David Dixon

Rui Xu

David A Mareska

Laurence Edward Burgess

Darren Martin Harvey

Ganghyeok Kim

Qian Zhao

George T Topalov

Mark Laurence Boys

Ralph P Robinson

Chang Rao

Robert Kirk DeLisle

April L Kennedy

Bryson Rast

Youngboo Kim

Guy Vigers

Devan Balachari

Steven Wayne Goldstein

Nathan B Mantlo

Gerald F Holland

Bernard Hulin

Jeffery A Zablocki

Robert D Groneberg

Erik James Hicken

Brad Newhouse

Fredrik Pehr Marmsater

David A Clark

Robert D Gronenberg

Eugene Tarlton, Jr

Ellen Ruth Laird

Terry J Rosen

Arthur A Nagel

Anthony D Piscopio

Charles Todd Eary

Daniel John Watson

Fredrik P Marmsäter

Karl Bedke

Joseph P Lyssikatos

Shelley Allen

Rodney C Schnur

David James Rawson

John E Robinson

Kevin W Hunt

Christopher T Clark

Nicholas C Kallan

Robert Kirk Delisle

Julie Marie Greschuk

D David Hennings

Michael F Bradley

Matthew David Medina

Laurence E Burges

Heli Huang

Keshi Wang

Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.

Compositions and methods for inhibiting CD73

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Aryl ethers and uses thereof

The present disclosure provides compounds of Formula (II)  wherein R, R, R, R, R, W, W, W, X, Y, and A are as described herein. The disclosed compounds modulate CD73 activity. The present disclosure also provides, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity.

CD73 inhibitors and uses thereof

Disclosed herein are substituted indane derivatives useful as HIF-2&#x3b1; inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2&#x3b1; activity are also disclosed.

Aromatic compounds and uses thereof

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

The present disclosure relates to HIF-2&#x3b1; inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2&#x3b1; scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

Benzimidazole derivatives and uses thereof

The present disclosure relates to cyclic sulfones and sulfoximines that are HIF-2a inhibitors and methods of making and using them for treating cancers. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier or excipient. The compound may exist in an amorphous form, a crystalline form, or as a salt, solvate, or hydrate. In another aspect, the present disclosure provides a method of treating renal cell carcinoma by administrating a therapeutically effective amount of a compound described herein or a pharmaceutical composition thereof to a subject in need of such treatment.

Cyclic sulfone and sulfoximine analogs and uses thereof

Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal. 

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain. 

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors

Growing community of inventors

Boulder, CO, United States of America

James P Rizzi